Multiple interventions to try for HIV remission in people on ART

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 trial investigates a multifaceted strategy to achieve HIV remission in adults on stable ART. The approach combines intensified antiretroviral therapy to reduce residual replication, a novel latency-reversal agent regimen, and autologous dendritic cell therapy loaded with HIV peptides. The study will use genomic, metabolomic, and transcriptomic analyses to understand mechanisms of persistence in a resource-constrained setting and to personalize interventions. Participants will be monitored for virologic rebound, immunologic responses, and safety throughout the treatment period and follow-up. The trial builds on prior work in Brazil to adapt cure strategies for local populations while evaluating potential for durable viral control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\> 18 years old Documented HIV-1 infection. Has voluntarily signed ICF. On HAART ≥ 2 years, without changes in the 24 weeks immediately prior to screening.

HIV viral load \<50 copies/mL, and never \> 50 copies/mL on 2 consecutive occasions in the last 2 years. CD4 count nadir.

\> 350 cells/ mm3 Current CD4 count \> 500 cells/ mm3. R5 HIV-1 at Screening as defined by proviral DNA genotropism.

Exclusion Criteria:

A subject will NOT be eligible for study participation if he/she meets ANY of the following criteria:

Any evidence of an active AIDS-defining condition. Any significant acute medical illness in the past 8 weeks. Women who are pregnant or breastfeeding. Use of any of the following within 90 days prior to entry: systemic cytotoxic chemotherapy; investigational agents; immunomodulators (colony-stimulating factors, growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons); coumadin, warfarin, or other Coumadin derivative anticoagulants. Use of an agent definitely or possibly associated with effects on QT intervals: amiodarone, arsenic trioxide, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, clarithromycin, disopyramide, dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, pentamidine, pimozide, probucol, procainamide, quinidine, sotalol, sparfloxacin, terfenadine, thioridazine.

Receipt of compounds with HDAC inhibitor-like activity, such as valproic acid or nicotinamide within the last 30 days. Potential participants may enroll after a 30-day washout period.

Known hypersensitivity to the components of gold salt, nicotinamide or its analogs.

Hepatitis B (HBsAg +) or Hepatitis C (HCV RNA +) infection. Known renal insufficiency defined as calculated creatinine clearance (Cockcroft Gault formula) \<60 mL/min.

Subjects with a laboratory abnormality grade 3 or 4 with the following exceptions: pancreatic amylase, cholesterol, triglyceride, gamma glutamyl transpeptidase, bilirubin.

Any condition which, in the investigators opinion, could compromise the subject's safety or adherence to the trial protocol.

Where it's running

• Laboratório de Retrovirologia, UNIFESP
  São Paulo, São Paulo, Brazil Recruiting

Study contacts

• Study coordinator: Ricardo S Diaz, MD, PhD
• Email: rsdiaz@unifesp.br
• Phone: 55-11-5576-4834

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide

  This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.

  Recruiting Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Paris · NCT07921472

• Portable chest X-ray screening to rapidly find TB in migrants

  A community-based TB screening effort using mobile chest X-rays and AI-assisted readings is tested among migrant adults in New York City to see if it helps identify active TB earlier and connect people to care.

  Recruiting Columbia University · New York, New York · NCT07737275

• Two-probe thermal ablation for cervical precancer in WLWH in South Africa

  This study tests whether using two probes for thermal ablation is safer or more effective than one probe for treating cervical precancer in women living with HIV in South Africa.

  Recruiting Fred Hutchinson Cancer Center · Durban · NCT07645378

• Two-probe thermal ablation for cervical precancer in WLWH in Zimbabwe

  This study tests whether using two TA probes (endocervical and ectocervical) is better than one probe for treating cervical precancer in women living with HIV in Zimbabwe.

  Recruiting Fred Hutchinson Cancer Center · Harare · NCT07645352

• TransAction program to improve HIV prevention and care for transgender women in Ho Chi Minh City

  This trial will test whether TransAction—individual risk-reduction sessions, skill-building and group support, plus social events—helps transgender women in Ho Chi Minh City move forward in HIV prevention and care compared with social events alone.

  Recruiting University of California, Los Angeles · Ho Chi Minh City · NCT07495059

• Restarting HIV treatment with a single-pill regimen (B/F/TAF) after a treatment gap

  This study tests whether quickly restarting ART with the single-pill regimen B/F/TAF is safe and effective for people with HIV who have had a treatment interruption of at least 12 weeks.

  Recruiting at 10 sites Phase 4 CAN Community Health · Clearwater, Florida and 9 other locations · NCT07476339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.